Literature DB >> 18317073

What to do with "Surprise" N2?: intraoperative management of patients with non-small cell lung cancer.

Frank Detterbeck1.   

Abstract

There is debate about how patients should be managed when malignant involvement of mediastinal lymph nodes is encountered at the time of lung resection. A comprehensive review of the literature demonstrates that differences in which outcomes are reported and how extensively patients were staged preoperatively explain much of the conflicting data. Certain negative and positive prognostic factors can be defined, but in general the outcomes justify proceeding with resection unless it is clear that disease will be left behind. Reasonable arguments can be made that the approach should include a mediastinal lymph node dissection and adjuvant therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18317073     DOI: 10.1097/JTO.0b013e3181630ebd

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  22 in total

1.  Prognostic Factors for Surgically Resected N2 Non-small Cell Lung Cancer.

Authors:  Keishi Kawasaki; Yasunori Sato; Yoshio Suzuki; Haruhisa Saito; Yukihiro Nomura; Yukihiro Yoshida
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-01-26       Impact factor: 1.520

Review 2.  Radiotherapy for single station N2 NSCLC.

Authors:  Jan P van Meerbeeck
Journal:  Transl Lung Cancer Res       Date:  2014-08

3.  Surgery in microscopically pathological N2 non-small cell lung cancer: the size of lymph node matters.

Authors:  Ming-Ching Lee; Chung-Ping Hsu
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

4.  The importance of the false-negative rate to validate a staging protocol for non-small cell lung cancer.

Authors:  Carme Obiols; Sergi Call; Ramon Rami-Porta
Journal:  Transl Lung Cancer Res       Date:  2019-12

5.  Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis.

Authors:  Chi-Fu Jeffrey Yang; Arvind Kumar; Brian C Gulack; Michael S Mulvihill; Matthew G Hartwig; Xiaofei Wang; Thomas A D'Amico; Mark F Berry
Journal:  J Thorac Cardiovasc Surg       Date:  2015-12-21       Impact factor: 5.209

6.  The Significance of Upfront Knowledge of N2 Disease in Non-small Cell Lung Cancer.

Authors:  Daniel C Thomas; Brian N Arnold; Joshua E Rosen; Michelle C Salazar; Frank C Detterbeck; Justin D Blasberg; Daniel J Boffa; Anthony W Kim
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

7.  Using pet-ct to reduce futile thoracotomy rates in non-small-cell lung cancer: a population-based review.

Authors:  M Smoragiewicz; J Laskin; D Wilson; K Ramsden; J Yee; S Lam; T Shaipanich; Y Zhai; C Ho
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

Review 8.  Lung cancer surgery: an up to date.

Authors:  Nikolaos Baltayiannis; Michail Chandrinos; Dimitrios Anagnostopoulos; Paul Zarogoulidis; Kosmas Tsakiridis; Andreas Mpakas; Nikolaos Machairiotis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Nikolaos Courcoutsakis; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

9.  Results of video-assisted thoracic surgery versus thoracotomy in surgical resection of pN2 non-small cell lung cancer in a Chinese high-volume Center.

Authors:  Chengwu Liu; Chenglin Guo; Fanyi Gan; Jiandong Mei; Qiang Pu; Zheng Liu; Yunke Zhu; Hu Liao; Lin Ma; Feng Lin; Lunxu Liu
Journal:  Surg Endosc       Date:  2020-05-11       Impact factor: 4.584

Review 10.  Lymph node dissection for lung cancer: past, present, and future.

Authors:  Shun-ichi Watanabe
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.